Presentations Utrecht 2023
Presentations ESCCA 2023 Utrecht
Please note: not all presentations have been submitted yet. This page will be regularly updated in the course of November.
If you are not an ESCCA member, you can access the presentations until 20 December 2023.
ABSTRACT BOOK
Download the Abstract Book, containing the abstracts of the plenary sessions, best abstract presentations and poster presentations.
PRESENTATIONS PRE-CONFERENCE COURSES
The presentations of the Pre-conference workshops will be sent directly to the registered participants by the end of November/early December 2023.
PRESENTATIONS PLENARY SESSIONS
PLE01: Keynote Lecture: Advances in monitoring immunotherapies
- Petra Reinke - MonitoringTreg therapy in SOT
PLE-02: ESCCA-ICCS joint session: Standardization in Clinical Flow Cytometry: Design, Validation, and Analysis
- Virginia Litwin - Using CLSI H62 to Bring Quality to the Clinical Flow Cytometry Laboratory
- Ahmad Al-Attar - Education leads to standardization
- Wolfgang Kern - Standardization in MRD AML
PLE03: ESCCA-EHA joint session: Clinical results in Measurable Residual Disease (MRD)-driven trials
- Andy Rawstron - The role of MRD in current treatment strategies for CLL
- Noemi Puig - Role of minimal residual disease in multiple myeloma: different techniques for a crucial biomarker
PLE05: ESCCA-ESID joint session
- Mirjam van der Burg: B-cell development in a new context: new insights based on inborn errors of immunity
PLE06: Immunology: Interactive Case Presentation
- Mirjam van der Burg: Interactive cases on inborn errors of immunity
PLE08: Keynote Lecture
PLE09: Hemato-Oncology: Interactive Case Presentation
PRESENTATIONS PARALLEL SESSIONS
Advances in hemato-oncological diseases
PAR01: The WHO2022/ICC new classifications: what has changed in the diagnostic approach to hematological malignancies?
- Kees Meijer & Maximiliano Ramia De Cap
PAR04: Headline 2023 news in cellular therapy of hematological malignancies
- Monica Guzman - Targeting CD123 from immunotherapy to CART: BPDCN and beyond
- Reuben Benjamin - CAR T cell treatment for CD19 positive malignancies
PAR07: Machine learning approaches in flow-cytometry analysis
- Sarah Bonte - Translating computational flow cytometry to the clinic
- Margarita Maurer-Granofszky & Michael Reiter - Machine learning for automated FLOW-MRD assessment
PAR10: Dissecting complexity of Hematological malignancies
- Lydia Campos - Phenotypic myeloid alterations in Monoclonal Gammopathy of undetermined significance and in de novo myeloma patients
- Catia Simoes - Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
PAR13: New developments PNH treatment and diagnostics
- Frank Preijers - Developments in diagnostics to monitor PNH clones and complement activation
- Bruno Fattizzo - Modern treatment approaches to PNH treatment
Validation approaches in clinical FC
PAR02: Validation and standardisation of functional assays
- José Enrique O'Connor - Functional assays of platelet in whole blood
- Hanna IJspeert - Phospho-assays for research and diagnostics of IEI
PAR05: How IVDR will change my lab
- Pieter Bogaert - IVDR and flow cytometry: impact on routine diagnostics and clinical trials
- Iuri Marinov - Assessment of Immature PNH RBCs (iRBCs) by Flow Cytometry: Assay Validation following the EU 2017/746-IVDR for In-house Devices
PAR08: A practical approach to IVDR
- Sylvie Freeman - Harmonization efforts in AML MRD
- Adrian Schwarzer - Development of full spectrum flow cytometry assays for the detection of measurable residual disease in acute myeloid leukemia
PAR11: Validation/harmonization of ALL-MRD
- Vincent van der Velden - Standardized flowcytometric MRD analysis in BCP-ALL patients
- Lukasz Sędek - Challenges in MRD analysis in T-ALL by flow cytometry
PAR14: Validated approach to T-cell/B-cell lympho-proliferative disorders diagnosis and monitoring
- Julia Almeida - New flow-cytometry approaches for diagnosis (of clonality), classification and monitoring of T-cell CLPD
- Massimo Geuna - B-LPD, diagnosis beyond typical immunophenotypic fingerprint entities
Cutting-edge immunology
PAR03: Towards the definition of the immunological ‘normal’ across different age groups
- Ester Mejstríková - Defining the normal: new approaches for harmonized subset definitions and gating procedures
- Jaromir Mikes - Minimize technical variation to see a more biological signal - optimized blood sampling methods in Systems Immunology
PAR06:Cytometry in neurological & psychiatric diseases
- Tilman Schneider-Hohendorf - Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis
- Marvin van Luijn - Defining T cells poised to infiltrate the brain and trigger multiple sclerosis
PAR09: Cytometry in the diagnosis of inborn errors of innate immunity
- Lisette van de Corput - Neutrophil oxidative burst capacity and NK cell function assays in cellular diagnostics
- Evelien Sprenkeler - Functional studies on inborn errors of innate immunity
PAR12: Autoimmunity, chronic inflammatory disease, and immune tolerance
- Carina Saggau - Ag-specific T-cells in autoimmunity
- Asbjørn Christophersen -Direct isolation of disease-driving T cells in celiac disease without using HLA multimers
PAR15: Clinical cytometry in transplantation
- Britt-Marie Ekman-Joelsson - Immunological differences between heart- and kidney-transplanted children
- Wouter Woud - Direct detection of single extracellular vesicles in kidney transplantation